HC Wainwright Cuts Black Diamond Therapeutics (NASDAQ:BDTX) Price Target to $10.00

Key Points

• HC Wainwright has lowered its price target for Black Diamond Therapeutics (NASDAQ:BDTX) from $12.00 to $10.00, while still maintaining a "buy" rating, indicating a potential upside of 316.67% from the current price.
• Recent evaluations from other brokerages include a downgrade from Wall Street Zen to a "hold" rating, while Raymond James Financial has raised the stock to "outperform" with a price target of $11.00.
• Black Diamond Therapeutics reported earnings of ($0.19) EPS for the quarter, exceeding analyst expectations of ($0.25), with a consensus rating of "Moderate Buy" and a target price of $12.40.

Black Diamond Therapeutics (NASDAQ:BDTX - Free Report) had its price objective lowered by HC Wainwright from $12.00 to $10.00 in a report published on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Black Diamond Therapeutics' Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at $0.33 EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.27) EPS and FY2026 earnings at ($1.04) EPS.

A number of other analysts have also recently weighed in on the stock. Raymond James Financial raised shares of Black Diamond Therapeutics to an "outperform" rating and set a $11.00 price objective on the stock in a report on Tuesday, July 1st. Wall Street Zen downgraded shares of Black Diamond Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Black Diamond Therapeutics currently has an average rating of "Buy" and a consensus target price of $12.40.

Black Diamond Therapeutics Stock Performance

BDTX stock traded down $0.07 during midday trading on Monday, reaching $2.73. 477,292 shares of the company were exchanged, compared to its average volume of 2,002,192. Black Diamond Therapeutics has a 1-year low of $1.20 and a 1-year high of $6.75. The stock's 50-day simple moving average is $2.65 and its 200 day simple moving average is $2.15. The company has a market cap of $155.16 million, a price-to-earnings ratio of 11.90 and a beta of 2.87.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.06. On average, research analysts anticipate that Black Diamond Therapeutics will post -1.3 earnings per share for the current year.

Hedge Funds Weigh In On Black Diamond Therapeutics

Several institutional investors have recently bought and sold shares of the company. DLK Investment Management LLC boosted its position in shares of Black Diamond Therapeutics by 26.3% in the 2nd quarter. DLK Investment Management LLC now owns 20,200 shares of the company's stock worth $50,000 after buying an additional 4,200 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Black Diamond Therapeutics by 41.8% in the 4th quarter. Wells Fargo & Company MN now owns 20,119 shares of the company's stock worth $43,000 after buying an additional 5,932 shares in the last quarter. Barclays PLC boosted its position in shares of Black Diamond Therapeutics by 10.7% in the 4th quarter. Barclays PLC now owns 86,545 shares of the company's stock worth $186,000 after buying an additional 8,394 shares in the last quarter. CWM LLC boosted its position in shares of Black Diamond Therapeutics by 212.2% in the 2nd quarter. CWM LLC now owns 14,338 shares of the company's stock worth $36,000 after buying an additional 9,746 shares in the last quarter. Finally, R Squared Ltd purchased a new position in Black Diamond Therapeutics in the 2nd quarter valued at about $25,000. 95.47% of the stock is owned by institutional investors and hedge funds.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.